Quotient Sciences Recognized as a Winner of 2025 CDMO Leadership Awards
Read More66 - 70 of 154 results
John McDermott discusses the latest trends in drug development outsourcing with Biopharm International.
Learn more
Over the past 30 years, Quotient Sciences has worked on over 3,000 molecules across all stages of development. SpeakPharma interviews Eleanor Row, our Executive Director of Commercial who discusses the challenges that drug developers should...
Learn more
Quotient Sciences has supported Evecxia with the Phase 1 two-part single ascending dose (SAD) and multiple ascending dose (MAD) trial of EVX-101 in healthy volunteers treated with escitalopram. Favorable safety, tolerability, pharmacokineti...
Learn more
Crinetics Pharmaceuticals announces CRN04894 pediatric program in partnership with Quotient Sciences. The partnership will utilize Quotient Sciences’ unique Translational Pharmaceutics® platform to provide integrated formulation development...
Learn more
NOTTINGHAM, UK; March 28, 2023 – Quotient Sciences, the drug development and manufacturing accelerator, today announced that it has grown the workforce at its Alnwick, UK, facility by 20% over the past 2 years. The Alnwick site’s growth has...
Learn more
